Response to bortezomib therapy for multiple myeloma (MM) in actual clinical practice: Preliminary effectiveness findings of an international observational study

被引：0
|
作者：
Delforge, Michel [1 ]
Katodritou, Eirini [2 ]
Zervas, Konstantinos [2 ]
Sargin, Deniz [3 ]
Hulin, Cyrille [4 ]
Linderholm, Mats [5 ]
Verrou, Evgenia [2 ]
Poon, Vicki [6 ]
Dhawan, Ravinder [6 ]
机构：
[1] Univ Hosp Leuven, Dept Hematol, Louvain, Belgium
[2] Theagenion Canc Ctr, Dept Hematol, Thessaloniki, Greece
[3] Istanbul Univ, Dept Internal Med, Div Hematol, Istanbul, Turkey
[4] Univ Nancy Brabois, Ctr Hosp, Vandoeuvre Les Nancy, France
[5] Linkoping Univ Hosp, Dept Haematol, S-58185 Linkoping, Sweden
[6] Johnson & Johnson, Raritan, NJ USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.4837.4837
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4837
引用
收藏
页码：284B / 284B
页数：1
相关论文
共 50 条
  • [31] Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide
    Prince, H. M.
    Schenkel, B.
    Mileshkin, L.
    LEUKEMIA, 2007, 21 (04) : 818 - 820
  • [32] Risk of Progression and Survival in Newly Diagnosed Multiple Myeloma Patients Non-Responsive to Bortezomib-Based Induction Therapy: an Observational Multicenter International Study
    Cohen, Yael C.
    Joffe, Erel
    Benyamini, Noam
    Dimopoulos, Meletios A.
    Trestman, Svetlana
    Held, Viki
    Avivi, Irit
    Kastritis, Efstathios
    BLOOD, 2014, 124 (21)
  • [33] Erratum: Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
    S K Kumar
    J H Lee
    J J Lahuerta
    G Morgan
    P G Richardson
    J Crowley
    J Haessler
    J Feather
    A Hoering
    P Moreau
    X LeLeu
    C Hulin
    S K Klein
    P Sonneveld
    D Siegel
    J Bladeé
    H Goldschmidt
    S Jagannath
    J S Miguel
    R Orlowski
    A Palumbo
    O Sezer
    S V Rajkumar
    Leukemia, 2012, 26 : 1153 - 1153
  • [34] Efficacy of Bortezomib Plus Dexamethasone Versus Bortezomib Monotherapy In Patients with Relapsed/Refractory Multiple Myeloma: An Interim Report from an International Electronic Observational Study.
    Dimopoulos, Meletios A.
    De Samblanx, Hadewijch M.
    Roussou, Maria G.
    Zervas, Konstantinos
    Katodritou, Eirini
    Sargin, Deniz
    Hulin, Cyrille
    Ahlberg, Lucia
    De La Rubia, Javier
    Ganguly, Rita
    Diels, Joris K.
    van de Velde, Helgi
    Dhawan, Ravinder
    Spencer, Michael D.
    Delforge, Michel
    BLOOD, 2010, 116 (21) : 1247 - 1248
  • [35] EFFICACY OF BORTEZOMIB-BASED THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: Results FROM AN ELECTRONIC BORTEZOMIB OBSERVATIONAL STUDY (EVOBS) FOR PATIENT ENROLLED IN RUSSIAN FEDERATION
    Abdulkadyrov, K.
    Schmidt, A.
    Voloshin, S.
    Shuvaev, V.
    Kuvshinov, A.
    HAEMATOLOGICA, 2012, 97 : 598 - 599
  • [36] Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) in patients with relapsed or relapsed/refractory multiple myeloma (MM): Preliminary results of a phase II study
    Richardson, Paul
    Jagannath, Sundaf
    Raje, Noopur
    Jakubowiak, Andrzej
    Lonial, Sagar
    Ghobrial, Irene
    Schlossman, Robert
    Mazumder, Amitabha
    Munshi, Nikhil
    Colson, Kathleen
    McKenney, Mary
    Farrell, Melissa
    Lunde, Laura
    Giove, Lawrence
    Kaster, Sarah
    Mitsiades, Constantine
    Hideshima, Teru
    Knight, Robert
    Esseltine, Dixie-Lee
    Anderson, Kenneth
    BLOOD, 2007, 110 (11) : 797A - 797A
  • [37] EFFICACY AND SAFETY OF BORTEZOMIB-BASED RETREATMENT IN MULTIPLE MYELOMA (MM) PATIENTS RELAPSING AFTER BORTEZOMIB-CONTAINING FIRST-LINE THERAPY: A RETROSPECTIVE STUDY
    Oriol, A.
    Giraldo, P.
    Kotsianidis, I.
    Couturier, C.
    Angermund, R.
    Broer, E.
    Corso, A.
    HAEMATOLOGICA, 2012, 97 : 609 - 610
  • [38] Efficacy and safety of bortezomib in patients with refractory and relapsed multiple myeloma (MM) outside clinical trials: Results from the catalan myeloma/amyloid study group (Gemmac)
    Cibeira, M. T.
    Garcia, A.
    Rosinol, L.
    Petit, J.
    Oriol, A.
    Abella, E.
    Soler, J. A.
    Plensa, E.
    Callis, M.
    Gonzalez, Y.
    Macia, J.
    Orriols, J.
    Escoda, L.
    Tutusaus, M.
    Heras, G.
    Monzo, S.
    Herranz, M. J.
    Garcia, M.
    Sureda, A.
    Blade, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 157 - 157
  • [39] A Multicenter Observational Retrospective Study of Second-Line Treatment With Daratumumab-Bortezomib-Dexamethasone (DaraVd) in Multiple Myeloma (MM) Patients Refractory to Lenalidomide
    Rizzello, Ilaria
    Sacchetti, Ilaria
    Barbato, Simona
    Solli, Vincenza
    Stefanoni, Paola
    Cani, Lorenzo
    Pavan, Laura
    Quaresima, Micol
    Belotti, Angelo
    Sgherza, Nicola
    Gentile, Massimo
    Barila, Gregorio
    Patriarca, Francesca
    Celli, Melania
    Vincelli, Iolanda Donatella
    Mancuso, Katia
    Sartor, Chiara
    Pantani, Lucia
    Tacchetti, Paola
    Talarico, Marco
    Puppi, Michele
    Bigi, Flavia
    Cavo, Michele
    Zamagni, Elena
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S275 - S275
  • [40] Targeting Complete Response with Upfront Bortezomib Followed By Autologous Transplantation and Consolidation Therapy for Untreated Multiple Myeloma (TUBA study)
    Nakasone, Hideki
    Terasako-Saito, Kiriko
    Hirano, Teiichi
    Wake, Atsushi
    Shimizu, Seiichi
    Yamazaki, Etsuko
    Akazawa, Kouhei
    Usuki, Kensuke
    Chiba, Shigeru
    Minauchi, Koichiro
    Miyaoka, Etsuo
    Ota, Shuichi
    Taniguchi, Shuichi
    Kanda, Yoshinobu
    BLOOD, 2016, 128 (22)
12345